Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)

Abstract Background To compare the efficacy and safety of postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy with radiotherapy only for the postoperative treatment of esophageal squamous cell carcinoma. Methods This trial was a single-arm phase...

Full description

Bibliographic Details
Published in:Radiation Oncology
Main Authors: Dashan Ai, Yun Chen, Qi Liu, Jiaying Deng, Xiaofei Zhang, Junhua Zhang, Li Chu, Jingyi Shen, Longfei Ma, Yawei Zhang, Haiquan Chen, Longsheng Miao, Kuaile Zhao, Jiaqing Xiang
Format: Article
Language:English
Published: BMC 2023-02-01
Subjects:
Online Access:https://doi.org/10.1186/s13014-023-02211-w
_version_ 1852655426430042112
author Dashan Ai
Yun Chen
Qi Liu
Jiaying Deng
Xiaofei Zhang
Junhua Zhang
Li Chu
Jingyi Shen
Longfei Ma
Yawei Zhang
Haiquan Chen
Longsheng Miao
Kuaile Zhao
Jiaqing Xiang
author_facet Dashan Ai
Yun Chen
Qi Liu
Jiaying Deng
Xiaofei Zhang
Junhua Zhang
Li Chu
Jingyi Shen
Longfei Ma
Yawei Zhang
Haiquan Chen
Longsheng Miao
Kuaile Zhao
Jiaqing Xiang
author_sort Dashan Ai
collection DOAJ
container_title Radiation Oncology
description Abstract Background To compare the efficacy and safety of postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy with radiotherapy only for the postoperative treatment of esophageal squamous cell carcinoma. Methods This trial was a single-arm phase II trial. Patients who underwent a radical transthoracic resection with negative margins within 3 months and histologically confirmed esophageal squamous cell carcinoma (pT3-4N0M0 or pTxN + M0, AJCC 7th) were eligible for this study. Postoperative radiotherapy was performed at a total dose of 45 Gy in 25 fractions with clinical target volumes of the tumor bed, anastomosis, bilateral supraclavicular, mediastinal, left gastric and celiac trunk lymph node areas. Five cycles of weekly TC (paclitaxel 50 mg/m2, d1, carboplatin AUC = 2, d1) were given as concurrent chemotherapy. The primary endpoint was the 2-year local control rate, and the secondary endpoints were overall survival, disease free survival, local-regional recurrence free survival, distant metastasis free survival and adverse events. All endpoints were compared with those in ESO-Shanghai 8 study with postoperative radiotherapy alone (40 Gy/20Fx). Results A total of 70 patients were enrolled from 2016 to 2018. The 2-year local control rate was 87.9% (95% CI: 83.3–92.3) in this study, which achieved the hypothesized 2-year local control rate of at least 83%. Overall survival, disease free survival, local-regional recurrence free survival and distant metastasis free survival in this study were also longer than those in previous ESO-Shanghai 8 study while most toxicities were increased and two patients in this study died of radiation pneumonitis. Conclusions Postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy was effective. Treatment related toxicity was increased due to higher treatment intensity. Trial registration clinicaltrials.gov: NCT02916511.
format Article
id doaj-art-4cb07df514b94dcea88ffc5e2b6a9802
institution Directory of Open Access Journals
issn 1748-717X
language English
publishDate 2023-02-01
publisher BMC
record_format Article
spelling doaj-art-4cb07df514b94dcea88ffc5e2b6a98022025-08-19T21:39:11ZengBMCRadiation Oncology1748-717X2023-02-011811810.1186/s13014-023-02211-wExtensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)Dashan Ai0Yun Chen1Qi Liu2Jiaying Deng3Xiaofei Zhang4Junhua Zhang5Li Chu6Jingyi Shen7Longfei Ma8Yawei Zhang9Haiquan Chen10Longsheng Miao11Kuaile Zhao12Jiaqing Xiang13Department of Radiation Oncology, Fudan University Shanghai Cancer CenterDepartment of Radiation Oncology, Fudan University Shanghai Cancer CenterDepartment of Radiation Oncology, Fudan University Shanghai Cancer CenterDepartment of Radiation Oncology, Fudan University Shanghai Cancer CenterDepartment of Radiation Oncology, Fudan University Shanghai Cancer CenterDepartment of Radiation Oncology, Fudan University Shanghai Cancer CenterDepartment of Radiation Oncology, Fudan University Shanghai Cancer CenterDepartment of Radiation Oncology, Fudan University Shanghai Cancer CenterDepartment of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Radiation Oncology, Fudan University Shanghai Cancer CenterDepartment of Oncology, Shanghai Medical College, Fudan UniversityAbstract Background To compare the efficacy and safety of postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy with radiotherapy only for the postoperative treatment of esophageal squamous cell carcinoma. Methods This trial was a single-arm phase II trial. Patients who underwent a radical transthoracic resection with negative margins within 3 months and histologically confirmed esophageal squamous cell carcinoma (pT3-4N0M0 or pTxN + M0, AJCC 7th) were eligible for this study. Postoperative radiotherapy was performed at a total dose of 45 Gy in 25 fractions with clinical target volumes of the tumor bed, anastomosis, bilateral supraclavicular, mediastinal, left gastric and celiac trunk lymph node areas. Five cycles of weekly TC (paclitaxel 50 mg/m2, d1, carboplatin AUC = 2, d1) were given as concurrent chemotherapy. The primary endpoint was the 2-year local control rate, and the secondary endpoints were overall survival, disease free survival, local-regional recurrence free survival, distant metastasis free survival and adverse events. All endpoints were compared with those in ESO-Shanghai 8 study with postoperative radiotherapy alone (40 Gy/20Fx). Results A total of 70 patients were enrolled from 2016 to 2018. The 2-year local control rate was 87.9% (95% CI: 83.3–92.3) in this study, which achieved the hypothesized 2-year local control rate of at least 83%. Overall survival, disease free survival, local-regional recurrence free survival and distant metastasis free survival in this study were also longer than those in previous ESO-Shanghai 8 study while most toxicities were increased and two patients in this study died of radiation pneumonitis. Conclusions Postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy was effective. Treatment related toxicity was increased due to higher treatment intensity. Trial registration clinicaltrials.gov: NCT02916511.https://doi.org/10.1186/s13014-023-02211-wEsophageal cancerPostoperative treatmentRadiotherapyChemotherapy
spellingShingle Dashan Ai
Yun Chen
Qi Liu
Jiaying Deng
Xiaofei Zhang
Junhua Zhang
Li Chu
Jingyi Shen
Longfei Ma
Yawei Zhang
Haiquan Chen
Longsheng Miao
Kuaile Zhao
Jiaqing Xiang
Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)
Esophageal cancer
Postoperative treatment
Radiotherapy
Chemotherapy
title Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)
title_full Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)
title_fullStr Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)
title_full_unstemmed Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)
title_short Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)
title_sort extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma a phase ii clinical trial eso shanghai 9
topic Esophageal cancer
Postoperative treatment
Radiotherapy
Chemotherapy
url https://doi.org/10.1186/s13014-023-02211-w
work_keys_str_mv AT dashanai extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT yunchen extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT qiliu extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT jiayingdeng extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT xiaofeizhang extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT junhuazhang extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT lichu extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT jingyishen extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT longfeima extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT yaweizhang extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT haiquanchen extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT longshengmiao extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT kuailezhao extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9
AT jiaqingxiang extensiveclinicaltargetvolumeinpostoperativechemoradiotherapyforesophagealsquamouscellcarcinomaaphaseiiclinicaltrialesoshanghai9